Learn Before
Concept

Results of CoVLP Phase 1 Trial

  • all dosages and combinations were well-tolerated, but adjuvants significantly increased reactogenicity (especially after dose 2)
  • CoVLP+AS03(adjuvant) had the most severe and frequent adverse. This group also had the highest immunogenicity after dose 1.
  • After the first dose, only a weak humoral response. After the second dose, modest cellular responses were elicited.

0

1

Updated 2020-11-23

Contributors are:

Who are from:

Tags

SARS-CoV-2 (COVID-19)

Biomedical Sciences